Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.31 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.31 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9000422 | 0.81 | HPGD (0.35) | HPGD | |
| SCHEMBL56361 | 0.81 | MAPT (0.40) | HPGDGRIK2MAPT | |
| SCHEMBL30017431 | 0.80 | HPGD (0.33) | HPGD | |
| SCHEMBL5493491 | 0.78 | HPGD (0.32) | HPGD | |
| SCHEMBL28660752 | 0.78 | MAPT (0.38) | HPGDGRIK2MAPT | |
| SCHEMBL7596929 | 0.78 | MAPT (0.38) | HPGDGRIK2MAPT | |
| SCHEMBL12937609 | 0.78 | MAPT (0.33) | HPGDCLK1CLK2DYRK1AHIPK1 | |
| SCHEMBL9651755 | 0.78 | NR1H2 (0.50) | NR1H2NR1H3HPGD | |
| SCHEMBL16033335 | 0.78 | HPGD (0.33) | HPGD | |
| SCHEMBL11910715 | 0.75 | HPGD (0.50) | HPGDACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922621-B | Polyorganosiloxane compositions with metal-based N-heterocyclic carbene condensation reaction catalysts and methods of making the same | 美国道康宁公司 | 2021-05-14 | — | — | CN | disclosed |
| CN-108779333-B | Moisture curable compositions | 美国陶氏有机硅公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-2268255-B1 | PREPARATION OF SILICONE MICROEMULSIONS | DOW SILICONES CORP (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10717821-B2 | Moisture curable compositions | DOW SILICONES CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| US-10308838-B2 | Moisture curable compositions | DOW SILICONES CORPORATION (US) | 2019-06-04 | — | — | US | disclosed |
| EP-3328918-B1 | POLYORGANOSILOXANE COMPOSITIONS WITH METAL BASED N-HETEROCYCLIC CARBENE CONDENSATION REACTION CATALYSTS AND METHODS FOR THE PREPARATION THEREOF | DOW SILICONES CORP (US) | 2019-05-15 | — | — | EP | disclosed |
| US-10287397-B2 | Polyorganosiloxane compositions with metal based N-heterocyclic carbene condensation reaction catalysts and methods for the preparation thereof | DOW CORNING CORPORATION (US) | 2019-05-14 | — | — | US | disclosed |
| US-20190048146-A1 | MOISTURE CURABLE COMPOSITIONS | DOW SILICONES CORPORATION | 2019-02-14 | — | — | US | disclosed |
| EP-3433320-A1 | MOISTURE CURABLE COMPOSITIONS | Dow Silicones Corporation (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2061828-B1 | SILICONE POLYMER EMULSIONS | DOW SILICONES CORP (US) | 2018-11-21 | — | — | EP | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| US-20030152623-A1 | Responsive microgel and methods related thereto | SUPRATEK PHARMA INC. (CA) | 2003-08-14 | — | — | US | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5317069-A | Photoresists | NATIONAL SCIENCE COUNCIL (TW) | 1994-05-31 | — | — | US | disclosed |
| EP-0259977-A2 | Tertiary amine compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1988-03-16 | — | — | EP | disclosed |
| US-4263401-A | Thermoplastic, elastomeric polystyrene/diorganopolysiloxane block copolymers | RHONE-POULENC INDUSTRIES (FR) | 1981-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287397-B2 | Polyorganosiloxane compositions with metal based N-heterocyclic carbene condensation reaction catalysts and methods for the preparation thereof | NCAPH, SQLE, NCAPD2 | NR1H2 2543/4885NR1H3 2233/4885HPGD 700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.